BioNTech stops Phase 2 Cevumeran study
BioNTech has halted a Phase 2 study of its Cevumeran treatment candidate.
By DoomRadar · Published on DoomRadar .
Why it matters
The decision may affect development of a cancer treatment, but the supplied information indicates no wider immediate public-health threat.
Related source links
These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.
- BioNTech Aktie: Cevumeran-Studie in Phase 2 gestoppt ↗boerse-express.com · Recorded source date: Sep 2, 2026, 6:01 PM UTC
AI-assisted, source-based analysis. Methodology · Report a correction